Deepak L Bhatt

Summary

Affiliation: Cleveland Clinic Foundation
Country: USA

Publications

  1. ncbi Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:20-5. 2003
  2. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
  3. ncbi Emboli protection devices
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:45S-49S. 2004
  4. ncbi Bleeding complications during percutaneous coronary intervention
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:24S-29S. 2004
  5. ncbi Identification of and management approaches for the high-risk patient
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 98:22Q-29Q. 2006
  6. ncbi The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients
    David S Lee
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:46-51. 2004
  7. ncbi Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 148:263-8. 2004
  8. ncbi Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
  9. doi Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 101:4D-13D. 2008
  10. ncbi Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, OH, 44195, USA
    J Invasive Cardiol 17:283-7. 2005

Collaborators

Detail Information

Publications110 found, 100 shown here

  1. ncbi Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 41:20-5. 2003
    ..This study was designed to assess whether use of enoxaparin during percutaneous coronary intervention (PCI) increased bleeding compared with unfractionated heparin, in addition to background therapy with eptifibatide...
  2. ncbi Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events
    Deepak L Bhatt
    Cleveland Clinic, Cleveland, USA
    N Engl J Med 354:1706-17. 2006
    ..Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for atherothrombotic events...
  3. ncbi Emboli protection devices
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:45S-49S. 2004
    ..Emboli protection devices are needed that will provide optimal procedural efficacy and cause minimal or no provocation ofembolization during use...
  4. ncbi Bleeding complications during percutaneous coronary intervention
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:24S-29S. 2004
    ..g., glycoprotein IIb/IIIa inhibitors, aspirin, clopidogrel), and whether replacements for heparin, such as bivalirudin or enoxaparin, offer any advantages in terms of bleeding risk...
  5. ncbi Identification of and management approaches for the high-risk patient
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 98:22Q-29Q. 2006
    ..The results of the CHARISMA trial are expected to provide further information on the optimal management of patients with stable atherothrombosis with respect to both antiplatelet therapy and overall management...
  6. ncbi The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients
    David S Lee
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:46-51. 2004
    ....
  7. ncbi Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 148:263-8. 2004
    ..Whether dual antiplatelet therapy is superior to aspirin monotherapy for high-risk primary prevention and secondary prevention is unknown...
  8. ncbi Utilization of early invasive management strategies for high-risk patients with non-ST-segment elevation acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, Cleveland, Ohio 44195, USA
    JAMA 292:2096-104. 2004
    ....
  9. doi Anti-inflammatory agents and antioxidants as a possible "third great wave" in cardiovascular secondary prevention
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 101:4D-13D. 2008
    ....
  10. ncbi Issues in the management of antiplatelet therapy in patients undergoing surgical revascularization. A roundtable discussion
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, OH, 44195, USA
    J Invasive Cardiol 17:283-7. 2005
  11. ncbi Does creatinine kinase-MB elevation after percutaneous coronary intervention predict outcomes in 2005? Periprocedural cardiac enzyme elevation predicts adverse outcomes
    Deepak L Bhatt
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Ave, Desk F25, Cleveland, OH 44195, USA
    Circulation 112:906-15; discussion 923. 2005
  12. ncbi Percutaneous coronary intervention in nonagenarians: age before beauty?
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 71:531-2. 2008
  13. ncbi A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:401. 2005
    ..We sought to characterize the risk factors and treatments of a diverse contemporary population of patients with atherothrombosis...
  14. ncbi Interpreting the COURAGE trial. Is medical therapy as good as PCI in stable angina? Two views
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, OH 44195, USA
    Cleve Clin J Med 74:618, 620. 2007
  15. ncbi Can clopidogrel and aspirin lower mortality in patients with acute myocardial infarction?
    Deepak L Bhatt
    Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Nat Clin Pract Cardiovasc Med 3:182-3. 2006
  16. ncbi Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study
    Deepak L Bhatt
    Cleveland Clinic, Department of Cardiovascular Medicine, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am Heart J 154:137-43. 2007
    ..We sought to determine whether peroxisome proliferator-activated receptor gamma agonists had any beneficial effect on patients with metabolic syndrome undergoing percutaneous coronary intervention (PCI)...
  17. ncbi Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 49:1982-8. 2007
    ..The purpose of this study was to determine the possible benefit of dual antiplatelet therapy in patients with prior myocardial infarction (MI), ischemic stroke, or symptomatic peripheral arterial disease (PAD)...
  18. ncbi Effect of revascularization on mortality associated with an elevated white blood cell count in acute coronary syndromes
    Deepak L Bhatt
    Department of Cardiovascular Medicine Desk F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 92:136-40. 2003
    ..This finding supports a pivotal role for inflammation in acute coronary syndromes. Importantly, this study suggests that in-hospital revascularization may mitigate some of the excess risk due to inflammation...
  19. ncbi Embolization--a pathological mechanism in renal artery stenosis
    Deepak L Bhatt
    Interventional Cardiology Fellowship, Cleveland Clinic Foundation, Department of Cardiovascular Medicine, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    J Invasive Cardiol 16:196-7. 2004
  20. ncbi Scientific and therapeutic advances in antiplatelet therapy
    Deepak L Bhatt
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Nat Rev Drug Discov 2:15-28. 2003
    ..New insights at the cellular and genomic levels will probably generate novel drugs to inhibit platelet function more effectively and safely than previously possible...
  21. ncbi International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 295:180-9. 2006
    ..To date, no single international database has characterized the atherosclerosis risk factor profile or treatment intensity of individuals with atherothrombosis...
  22. ncbi Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 90:625-8. 2002
  23. ncbi Successful "pre-closure" of 7Fr and 8Fr femoral arteriotomies with a 6Fr suture-based device (the Multicenter Interventional Closer Registry)
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland Ohio, USA
    Am J Cardiol 89:777-9. 2002
  24. ncbi Heparin in peripheral vascular intervention--time for a change?
    Deepak L Bhatt
    Director, Interventional Cardiology Fellowship, Cleveland Clinic Foundation, Department of Cardiovascular Medicine Desk F25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 15:249-50. 2003
  25. ncbi Diffuse coronary disease and atherothrombosis: a rationale for long-term therapy to prevent recurrent ischemic events
    Deepak L Bhatt
    Interventional Cardiology Fellowship, The Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Desk F 25, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    J Invasive Cardiol 15:3B-9B; discussion 9B-10B. 2003
  26. ncbi Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:716-21. 2005
    ....
  27. doi Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    JACC Cardiovasc Interv 1:227-32. 2008
    ..We sought to examine the clinical outcomes of patients treated with drug-eluting stents (DES) compared with bare-metal stents (BMS) during primary angioplasty for ST-segment elevation myocardial infarction (STEMI)...
  28. ncbi Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study
    Gus Theodos
    Cleveland Clinic, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 81:294-300. 2013
    ..To investigate the safety and risk of vascular complications of arteriotomy closure devices (ACD) with the direct thrombin inhibitor bivalirudin in patients undergoing percutaneous coronary intervention (PCI)...
  29. doi Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction
    Andrew N Rassi
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 61:35-40. 2013
    ..This study explored temporal trends in the use of aldosterone antagonist therapy among eligible patients with post-acute myocardial infarction (AMI) and reduced ejection fraction and characteristics associated with use in clinical practice...
  30. ncbi Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 92:1468-71. 2003
    ..3%, 7.5%, 8.1%, and 7.1%, respectively (p=0.71). The incidence of bleeding complications was 6.6%, 5.9%, 6.9%, and 7.3%, respectively (p=0.81). ACT did not independently predict either ischemic or hemorrhagic complications...
  31. ncbi Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention
    Deepak P Vivekananthan
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Ohio 44195, USA
    Am J Cardiol 94:358-60. 2004
    ..Clopidogrel pretreatment attenuated the periprocedural increase in CRP by 65% and was independently associated with an attenuation in the CRP increase in a multivariate model...
  32. ncbi Patient characteristics associated with the choice of triple antithrombotic therapy in acute coronary syndromes
    Jeremiah P Depta
    Department of Internal Medicine Medicine Institute, Cleveland Clinic, Ohio, USA
    Am J Cardiol 104:1171-8. 2009
    ..In conclusion, for patients with ACS, atrial fibrillation and atrial flutter were most strongly associated with the use of triple therapy; however, this therapy was used less often than dual or single antiplatelet therapy...
  33. ncbi Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
    Peter B Berger
    Director, Center for Clinical Studies, 100 N Academy Ave, MC 44 00, Danville, PA 17822, USA
    Circulation 121:2575-83. 2010
    ..We sought to determine the frequency and time course of bleeding with DAPT in patients with established vascular disease or risk factors only; identify correlates of bleeding; and determine whether bleeding is associated with mortality...
  34. ncbi Culprit-only or multivessel revascularization in patients with acute coronary syndromes: an American College of Cardiology National Cardiovascular Database Registry report
    Sorin J Brener
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:140-6. 2008
    ..Although an early invasive strategy improves outcome in these patients, there are limited data on culprit-only, single-vessel (SV) percutaneous coronary intervention (PCI) or MV PCI in the NSTE ACS setting...
  35. ncbi Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting
    Philippe L L'Allier
    Department of Cardiology, The Cleveland Clinic Foundation, Cleveland, USA
    Can J Cardiol 19:1041-6. 2003
    ..Most studies have demonstrated similar outcomes and a more favourable safety profile supporting this change in practice patterns...
  36. ncbi Feasibility of simultaneous bilateral carotid artery stenting
    Michael S Chen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 61:437-42. 2004
    ..There were no procedural deaths, myocardial infarctions, or strokes. Thus, among carefully selected patients, simultaneous bilateral carotid artery stenting is a promising, technically feasible option...
  37. ncbi An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial
    Thomas H Wang
    Cleveland Clinic, Cleveland, OH, USA
    Eur Heart J 28:2200-7. 2007
    ..aspirin alone in the prespecified 'asymptomatic' subgroup of CHARISMA, we investigated whether dual-antiplatelet therapy may be associated with adverse cardiovascular (CV) events in a primary prevention population...
  38. ncbi Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes
    Juhana Karha
    The Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 98:906-10. 2006
    ..92, 95% confidence interval 0.69 to 1.23, p = 0.59). In conclusion, adjunctive use of platelet GP IIb/IIIa inhibitors in saphenous vein graft PCI does not appear to be associated with less myonecrosis or improved survival...
  39. doi Bare metal stent thrombosis 13 years after implantation
    Michael L Sarkees
    Cleveland Clinic, Cleveland, OH, USA
    Cardiovasc Revasc Med 10:58-9. 2009
    ..Angiography demonstrated thrombotic occlusion and severe underlying restenosis of the stent. To our knowledge, this is the latest bare metal stent thrombosis described in the world medical literature...
  40. ncbi In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    J Am Coll Cardiol 49:849-54. 2007
    ....
  41. doi Ethnic differences in the prevalence and treatment of cardiovascular risk factors in US outpatients with peripheral arterial disease: insights from the reduction of atherothrombosis for continued health (REACH) registry
    Telly A Meadows
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, USA
    Am Heart J 158:1038-45. 2009
    ..Prior investigations to define ethnic-related differences in the risks, medical treatment, and outcomes of patients with peripheral arterial disease (PAD) have been limited...
  42. doi Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry
    EILEEN M HSICH
    College of Medicine, Cleveland Clinic, Cleveland, OH Electronic address
    Am Heart J 166:1063-1071.e3. 2013
    ..We sought to evaluate the relationship between sex, EF, and BNP in HF patients and determine prognostic significance of BNP as it relates to sex and EF...
  43. ncbi Symptomatic patients have similar outcomes compared with asymptomatic patients after carotid artery stenting with emboli protection
    Michael H Yen
    Departm, ent of Cardiovascular Nedicine F25, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 95:297-300. 2005
    ..Unlike surgical revascularization, symptomatic patients did not have a greater risk for stroke and death compared with asymptomatic patients after CAS with EPDs...
  44. ncbi Bare metal stent restenosis is not a benign clinical entity
    Michael S Chen
    The Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 151:1260-4. 2006
    ..We hypothesized that a substantial proportion of bare metal ISR presents as acute coronary syndromes. We aimed to characterize the severity of the clinical presentation of ISR...
  45. ncbi Risk of thrombosis with the use of sirolimus-eluting stents for percutaneous coronary intervention (from registry and clinical trial data)
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 95:1469-72. 2005
    ..Compared with bare metal stents, sirolimus-eluting stents did not appear to increase the risk for thrombosis up to 13.5 months after coronary intervention (risk ratio 0.49, 95% confidence interval 0.22 to 1.12, p = 0.09)...
  46. doi Association of hospital primary angioplasty volume in ST-segment elevation myocardial infarction with quality and outcomes
    Dharam J Kumbhani
    Cleveland Clinic, Cleveland, Ohio, USA
    JAMA 302:2207-13. 2009
    ..Earlier studies indicate an inverse relationship between hospital volume and mortality after primary angioplasty for patients presenting with ST-segment elevation myocardial infarction (STEMI). However, contemporary data are lacking...
  47. ncbi Real-world bare metal stenting: identification of patients at low or very low risk of 9-month coronary revascularization
    Stephen G Ellis
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Catheter Cardiovasc Interv 63:135-40. 2004
    ..Conversely, if the benefits of DESs are attenuated in routine practice, many groups of patients treated with BMSs may have nearly comparable results...
  48. ncbi Association between admission white blood cell count and one-year mortality in patients with acute coronary syndromes
    Michael H Yen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 115:318-21. 2003
  49. ncbi Thrombin, an ideal target for pharmacological inhibition: a review of direct thrombin inhibitors
    Hitinder S Gurm
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 149:S43-53. 2005
  50. doi The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials
    Dharam J Kumbhani
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:640-7. 2008
    ..Accordingly, our aim was to conduct a meta-analysis to assess the benefit and safety profile of drug-eluting stents in diabetic patients...
  51. ncbi Percutaneous coronary intervention in diabetics
    Juhana Karha
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Rev Endocr Metab Disord 5:277-85. 2004
  52. ncbi The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study: to what extent should the results be generalizable?
    Gregory P Gerschutz
    Department of Cardiology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 145:595-601. 2003
    ..Increased bleeding and greater requirements for blood transfusions were seen with clopidogrel. The addition of clopidogrel to aspirin represents a major advance in the treatment of acute coronary syndromes...
  53. doi Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up
    Henri Roukoz
    Department of Cardiovascular Medicine, University of Minnesota, Minneapolis, Minnesota, USA
    Am J Med 122:581.e1-10. 2009
    ..Several observational reports have documented both increased and decreased cardiac mortality or Q-wave myocardial infarction with drug-eluting stents compared with bare-metal stents...
  54. ncbi Impact of female sex on outcome after percutaneous coronary intervention
    John H Chiu
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:998-1002. 2004
    ..Prior reports have suggested that women have increased mortality compared to men following percutaneous coronary intervention (PCI). It remains unclear if this difference is secondary to sex or other confounding variables...
  55. ncbi GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention
    Jose E Exaire
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 148:1003-6. 2004
    ..We sought to analyze TMP after SVG-PCI with and without EPD and determine its impact on inhospital MACE...
  56. doi Sex differences in in-hospital mortality in acute decompensated heart failure with reduced and preserved ejection fraction
    EILEEN M HSICH
    College of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 163:430-7, 437.e1-3. 2012
    ..Other registries that compared patients with reduced and preserved EF did not analyze their data by sex. We sought to evaluate sex/EF differences in mortality and risk factors for survival in hospitalized patients with HF...
  57. doi Drug-eluting versus bare-metal stents for treating saphenous vein grafts
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44114, USA
    Am Heart J 158:637-43. 2009
    ..Current data show conflicting results regarding safety and efficacy of drug-eluting stents (DES) versus bare-metal stents (BMS) for treating saphenous vein grafts (SVG). Our objective was to compare DES with BMS for SVG intervention...
  58. ncbi Incremental effect of clopidogrel on important outcomes in patients with cardiovascular disease: a meta-analysis of randomized trials
    Thomas J Helton
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
    Am J Cardiovasc Drugs 7:289-97. 2007
    ..To quantify the impact of clopidogrel plus aspirin on the individual outcomes of death, myocardial infarction, or stroke in patients with established cardiovascular disease, or in patients with multiple risk factors for vascular disease...
  59. doi Drug-eluting stent fracture and acute coronary syndrome
    Adnan K Chhatriwalla
    Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cardiovasc Revasc Med 10:166-71. 2009
    ..Coronary stent fracture is an underrecognized entity but has been reported more frequently in the drug-eluting stent (DES) era. Nevertheless, the clinical implications of coronary stent fracture remain unclear...
  60. doi Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195 0002, USA
    JACC Cardiovasc Interv 2:329-36. 2009
    ..Our aim was to assess the incidence of all-cause mortality in patients with anemia undergoing percutaneous coronary intervention (PCI) receiving drug-eluting stents (DES) or bare-metal stents (BMS)...
  61. ncbi Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Circulation 105:691-6. 2002
    ..Therefore, we hypothesized that statin therapy has an early beneficial effect among patients undergoing PCI...
  62. ncbi Prediction of death or myocardial infarction by exercise single photon emission computed tomography perfusion scintigraphy in patients who have had recent coronary artery stenting
    Vivek Rajagopal
    Department of Cardiovascular, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 149:534-40. 2005
    ..We sought to determine if exercise nuclear testing provides independent prognostic information in patients after coronary stenting...
  63. ncbi Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Am Coll Cardiol 39:9-14. 2002
    ..We sought to determine whether clopidogrel is at least as efficacious as ticlopidine...
  64. ncbi The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention
    Robert B Fathi
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Am Heart J 150:1190-7. 2005
    ..We sought to assess the relationship among glomerular filtration rate (GFR), systemic inflammation, and long-term death after PCI...
  65. ncbi Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 48:1319-25. 2006
    ..This study sought to systematically determine whether early invasive therapy improves survival and reduces adverse cardiovascular events in the management of non-ST-segment elevation acute coronary syndromes...
  66. doi Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Am Heart J 155:1075-80. 2008
    ..The short-term and long-term safety and efficacy of paclitaxel versus sirolimus-overlapping drug-eluting stents (DES) is unknown. We sought to examine the clinical consequences of overlapping sirolimus versus paclitaxel DES...
  67. ncbi Long-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cardiac, Peripheral, and Carotid Intervention, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiovasc Drugs 7:135-41. 2007
    ..This study sought to determine if the initiation of statin (HMG-CoA reductase inhibitor) therapy during acute coronary syndromes reduces long-term mortality and other adverse cardiac outcomes...
  68. doi Safety and efficacy of carotid stenting in individuals with concomitant severe carotid and aortic stenosis
    Subrata Kar
    Department of Internal Medicine, Cleveland Clinic, Ohio, USA
    EuroIntervention 6:492-7. 2010
    ..Carotid artery stenting (CAS) prior to open-heart surgery may be a useful approach to minimise the risk of neurologic events in patients undergoing aortic valve replacement (AVR)...
  69. doi Platelet aspirin resistance in ED patients with suspected acute coronary syndrome
    Jonathan Glauser
    Cleveland Clinic, Case Western Reserve University, Cleveland, OH 44195, USA
    Am J Emerg Med 28:440-4. 2010
    ..The prevalence of emergency department (ED) platelet aspirin resistance in suspected acute coronary syndrome (ACS) is not described. Our purpose was to determine the prevalence of platelet aspirin resistance...
  70. doi Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 52:1041-8. 2008
    ..Our purpose was to examine the incidence of all-cause mortality among drug-eluting stents (DES) and bare-metal stents (BMS) while adjusting for many confounding factors generally not considered in prior studies...
  71. ncbi Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality
    Vivek Rajagopal
    The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Am J Cardiol 94:190-2. 2004
    ....
  72. ncbi Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction
    Albert W Chan
    Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Cardiol 89:132-6. 2002
    ....
  73. ncbi Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am J Med 119:1056-61. 2006
    ..Drug-eluting stents are commonly used for percutaneous coronary intervention. Despite excellent clinical efficacy, the association between drug-eluting stents and the risk for late thrombosis remains imprecisely defined...
  74. ncbi Clinical aspects of platelet inhibitors and thrombus formation
    Telly A Meadows
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
    Circ Res 100:1261-75. 2007
    ..The use of more refined agents in conjunction with a better understanding of their effects will further the ability to provide more optimized care on an individual basis...
  75. ncbi Case presentations and discussions
    Jeffrey Popma
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA
    J Invasive Cardiol 15:34B-41B. 2003
  76. ncbi Using statins to treat inflammation in acute coronary syndromes: Are we there yet?
    Mehdi H Shishehbor
    Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cleve Clin J Med 73:760-6. 2006
    ..In all the studies, the benefit correlated with reductions in CRP...
  77. ncbi Highlights of the 2002 update to the 2000 American College of Cardiology/American Heart Association acute coronary syndrome guidelines
    Michael S Chen
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Cardiol Rev 11:113-21. 2003
    ..This article summarizes the major modifications to the ACS guidelines and highlights the clinical evidence prompting such changes...
  78. ncbi Clinical outcomes in metabolic syndrome
    Rohit Bhatheja
    Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Cardiovasc Nurs 21:298-305. 2006
    ..Diagnosis and appropriate management of metabolic syndrome are challenges as the presence of risk factors predates the coronary event...
  79. ncbi Controversies of oral antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention
    Vivek Rajagopal
    Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio 44195, USA
    Semin Thromb Hemost 30:649-55. 2004
    ..This article will explore the current role of and controversies in oral antiplatelet therapy after ACS and PCI...
  80. ncbi Why diabetics are at risk in percutaneous coronary intervention and the appropriate management of diabetics in interventional cardiology
    Joel P Reginelli
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    J Invasive Cardiol 14:2E-10E; quiz 11E. 2002
    ....
  81. ncbi Clopidogrel and risk for acute coronary events
    Girish R Mood
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Desk F25, Cleveland, OH 44195, USA
    Curr Atheroscler Rep 9:401-8. 2007
    ..In this article, we review the benefits of clopidogrel as an antiplatelet agent and its role in the management of acute coronary syndromes and following percutaneous coronary intervention...
  82. ncbi Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive meta-analysis of randomized trials
    Anthony A Bavry
    Department of Cardiovascular Medicine, University of Florida, Gainesville, FL, USA
    Eur Heart J 29:2989-3001. 2008
    ..This study sought to determine whether the use of a thrombectomy or embolic protection device during revascularization for acute myocardial infarction reduces mortality compared with percutaneous coronary intervention (PCI) alone...
  83. ncbi What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: a meta-analysis
    Anthony A Bavry
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Am Coll Cardiol 45:941-6. 2005
    ..This study investigated the risk of stent thrombosis associated with the use of paclitaxel-eluting stents (PES) compared to bare-metal stents (BMS)...
  84. ncbi The CURE trial: using clopidogrel in acute coronary syndromes without ST-segment elevation
    Gregory P Gerschutz
    Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, OH 44195, USA
    Cleve Clin J Med 69:377-8, 380, 382 passim. 2002
    ..The benefit was at the cost of an increase in bleeding, however. This strategy may need to be tailored in centers that use a more aggressive treatment strategy of early angiography and revascularization...
  85. ncbi Aspirin and clopidogrel resistance: an emerging clinical entity
    Thomas H Wang
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Eur Heart J 27:647-54. 2006
    ....
  86. ncbi Need to test the arterial inflammation hypothesis
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
    Circulation 106:136-40. 2002
  87. pmc Cardiologists' and emergency physicians' perspectives on and knowledge of reperfusion guidelines pertaining to ST-segment-elevation myocardial infarction
    W Frank Peacock
    Department of Emergency Medicine, Cleveland Clinic, Cleveland, Ohio 44195 0002, USA
    Tex Heart Inst J 35:152-61. 2008
    ....
  88. doi Introduction. Oxidative stress and heart disease
    Deepak L Bhatt
    Department of Cardiovascular Medicine, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Am J Cardiol 101:1D-2D. 2008
  89. doi Meta-analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in Asians versus whites
    Gian M Novaro
    Department of Cardiology, Cleveland Clinic Florida, Weston, Florida, USA
    Am J Cardiol 101:506-9. 2008
    ..Further study is needed to investigate the mechanisms and potential genetic underpinnings behind this association...
  90. doi Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial
    Steven E Nissen
    Department of Cardiovascular Medicine and Cleveland Clinic Lerner School of Medicine, Cleveland, Ohio, USA
    JAMA 299:1547-60. 2008
    ..Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease...
  91. ncbi Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device
    Anthony A Bavry
    Department of Interventional Cardiology, Cleveland Clinic, 9500 Euclid Avenue, NO 605, Cleveland, OH 44114, USA
    J Invasive Cardiol 20:152-6. 2008
    ..The FISH (femoral introducer sheath and hemostasis) device is novel in that the access sheath and closure component are incorporated onto the same system...
  92. ncbi Clinical trials update from the annual scientific session of the American College of Cardiology 2006
    Christopher P Cannon
    Thrombolysis in Myocardial Infarction Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Am J Cardiol 98:36Q-41Q. 2006
  93. ncbi Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction
    J Emilio Exaire
    Instituto Nacional de Cardiologia, Mexico City, Mexico
    Arch Cardiol Mex 76:376-82. 2006
    ....
  94. ncbi Prevalence, predictors, and outcomes of patients with non-ST-segment elevation myocardial infarction and insignificant coronary artery disease: results from the Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early
    Manesh R Patel
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 152:641-7. 2006
    ..We sought to determine the prevalence, predictors, and outcomes of patients with NSTEMI and insignificant CAD...
  95. ncbi Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials
    Marco Roffi
    Division of Cardiology, University Hospital, Zurich, Switzerland
    Circulation 106:3063-7. 2002
    ..Despite widespread use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors for percutaneous coronary interventions (PCI) of bypass grafts, data supporting this strategy are lacking...
  96. ncbi One-year cardiovascular event rates in outpatients with atherothrombosis
    Ph Gabriel Steg
    Departement de Cardiologie, Hopital Bichat Claude Bernard, Paris, France
    JAMA 297:1197-206. 2007
    ....
  97. ncbi The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy
    Hitinder S Gurm
    Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, Michigan 48109 0311, USA
    J Invasive Cardiol 19:225-8. 2007
    ....
  98. ncbi Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease
    Steven R Steinhubl
    Division of Cardiology, University of Kentucky, Lexington, KY 40536 0200, USA
    Vasc Med 12:113-22. 2007
    ....
  99. ncbi Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial
    Jacqueline Saw
    Division of Cardiology, Vancouver General Hospital, University of British Columbia, Vancouver, British Columbia, Canada
    J Am Coll Cardiol 50:291-5. 2007
    ..The purpose of this study was to evaluate the potential impact of clopidogrel and statin interaction in a randomized, placebo-controlled trial with long-term follow-up...
  100. ncbi Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes
    Gerard X Brogan
    Department of Emergency Medicine, New York University School of Medicine North Shore Long Island Jewish Health System, Plainview, New York 11803, USA
    Diabetes Care 29:9-14. 2006
    ..The objective of this study was to characterize treatment patterns among patients with diabetes presenting with non-ST-segment elevation (NSTE) acute coronary syndromes (ACSs)...
  101. ncbi Aspirin and clopidogrel in acute coronary syndromes: therapeutic insights from the CURE study
    Hani Jneid
    Division of Cardiology, University of Louisville, Louisville, KY, USA
    Arch Intern Med 163:1145-53. 2003
    ..Aspirin resistance can be assessed through platelet aggregometry testing, measurement of urinary thromboxane metabolites, and, possibly, genomic testing in the future...